Entyvio (vedolizumab)

March 4, 2020March 4, 2020

Panel Recommends European Approval of Entyvio At-Home Injection

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of a subcutaneous (under-the-skin) injection of Entyvio (Vedolizumab), the gut-selective maintenance therapy for ... Read more

February 26, 2020February 26, 2020

New Entyvio Formulation – Given as Injection at Home – Leads to Crohn’s Remission After One Year, Takeda Announces

News

Maintenance therapy with Entyvio‘s new formulation as a subcutaneous, or under-the-skin injection (SC) led more people with moderate-to-severe, active Crohn’s disease (CD) to achieve clinical remission after one year, compared ... Read more

April 17, 2019April 17, 2019

Entyvio Improves Quality of Life, Work Productivity of Ulcerative Colitis Patients, Phase 3 Study Shows

News

Treatment with Entyvio (vedolizumab), delivered into the blood or under the skin, led to significant clinical improvements and in quality of life, as well as work productivity in patients with moderate-to-severe ... Read more

June 23, 2017June 22, 2017

Treatment Options: Biologic Medication Entyvio Is Next for Me

Columns, It Could Be Worse - a column by Mary Horsley

In a single article outside of my usual pattern of writing a series, I wanted to focus more on the biologic drugs and medications offered to Crohn’s disease and ulcerative ... Read more

October 5, 2016

Entyvio’s Effect in IBD Continues After Years of Treatment

News

Takeda recently published interim data showing that Entyvio (vedolizumab) treatment continues to be beneficial for people with ulcerative colitis or Crohn’s disease, whether or not they were treated with TNF-blockers at an earlier date. ... Read more